(0.63%) 5 078.25 points
(0.48%) 38 253 points
(0.74%) 17 568 points
(0.08%) $79.06
(2.17%) $1.974
(-0.42%) $2 301.30
(-1.62%) $26.32
(0.41%) $958.80
(0.22%) $0.935
(0.37%) $11.07
(0.14%) $0.800
(-1.45%) $91.91
@ $47.14
发出时间: 15 Feb 2024 @ 01:51
回报率: -0.13%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 5.65 %
Live Chart Being Loaded With Signals
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States...
Stats | |
---|---|
今日成交量 | 454 722 |
平均成交量 | 428 539 |
市值 | 2.28B |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.110 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -672.57 |
ATR14 | $0.108 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Colangelo Dominick | Buy | 6 002 | Stock Option (Right to Buy) |
2024-04-30 | Colangelo Dominick | Buy | 13 888 | Stock Option (Right to Buy) |
2024-04-30 | Colangelo Dominick | Buy | 5 555 | Common Stock |
2024-04-30 | Colangelo Dominick | Buy | 5 555 | Stock Option (Right to Buy) |
2024-04-30 | Colangelo Dominick | Buy | 6 002 | Common Stock |
INSIDER POWER |
---|
68.00 |
Last 100 transactions |
Buy: 883 338 | Sell: 166 323 |
音量 相关性
Vericel Corp 相关性 - 货币/商品
Vericel Corp 财务报表
Annual | 2023 |
营收: | $197.52M |
毛利润: | $135.58M (68.64 %) |
EPS: | $-0.0669 |
FY | 2023 |
营收: | $197.52M |
毛利润: | $135.58M (68.64 %) |
EPS: | $-0.0669 |
FY | 2022 |
营收: | $164.37M |
毛利润: | $109.79M (66.80 %) |
EPS: | $-0.350 |
FY | 2021 |
营收: | $156.18M |
毛利润: | $106.03M (67.88 %) |
EPS: | $-0.160 |
Financial Reports:
No articles found.
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。